The combination use of Jiangsu Hengrui Medicine’s camrelizumab and HLB Bio’s rivoceranib has received a novel drug approval from the National Medical Products Administration of China, HLB Bio announced Wednesday. 

Please refer to the following website for further details: 

https://news.koreaherald.com/view.php?ud=20230201000731&md=20230202003009_BL